Cargando…
CYP3A5 Gene-Guided Tacrolimus Treatment of Living-Donor Egyptian Kidney Transplanted Patients
BACKGROUND: Tacrolimus is an approved first-line immunosuppressive agent for kidney transplantations. Part of interindividual and interethnic differences in the response of patients to tacrolimus is attributed to polymorphisms at CYP3A5 metabolic enzyme. CYP3A5 gene expression status is associated w...
Autores principales: | Mendrinou, Effrosyni, Mashaly, Mohamed Elsayed, Al Okily, Amir Mohamed, Mohamed, Mohamed Elsayed, Refaie, Ayman Fathi, Elsawy, Essam Mahmoud, Saleh, Hazem Hamed, Sheashaa, Hussein, Patrinos, George P. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7431691/ https://www.ncbi.nlm.nih.gov/pubmed/32848803 http://dx.doi.org/10.3389/fphar.2020.01218 |
Ejemplares similares
-
The impact of CYP3A4 and CYP3A5 genetic variations on tacrolimus treatment of living‐donor Egyptian kidney transplanted patients
por: Wanas, Hanaa, et al.
Publicado: (2023) -
Impact of Donor Source on the Outcome of Live Donor Kidney Transplantation: A Single Center Experience
por: Matter, Yasser Elsayed, et al.
Publicado: (2016) -
Factors Affecting Graft Survival among Patients Receiving Kidneys from Live Donors: A Single-Center Experience
por: Ghoneim, Mohamed A., et al.
Publicado: (2013) -
Association between Epstein-Barr Virus Gene Polymorphism and Breast Cancer Risk among Egyptian Females
por: Mashaly, Mervat, et al.
Publicado: (2022) -
Service Value and Repurchase Intention in the Egyptian Fast-Food Restaurants: Toward a New Measurement Model
por: Doeim, Abdelhalim R., et al.
Publicado: (2022)